Development

Articles

The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Stable producer cell lines show real promise despite continued development challenges.

Exploring Producer Cell Development for Lentiviral Vector Manufacturing

Feliza Mirasol is the science editor for 

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

Despite many development challenges, stable producer cell lines show real promise.

State of Producer Cell Development for Lentiviral Vector Manufacturing

Chris Spivey is the editorial director of 

Lives are saved when time from vein to vein decreases.

Therapeutic Biologics and the Need for Speed

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Advances in In Vivo CAR T-cell Therapies

Decreasing vein to vein time saves lives.

High-titer Vector Producing Cells

In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.

Technology for In Vivo CAR T-cell Therapy Advances

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

Early Phase Development